

Claims

- 5 *Sub 133*
1. Use of a reversible selective inhibitor of monoamine oxidase A, reversible selective inhibitor of monoamine oxidase B or a reversible mixed inhibitor of monoamine oxidase A and B for the manufacture of drugs intended for the treatment of obesity.
 - 10 2. Use of a reversible mixed inhibitor of monoamine oxidase A and B according to claim 1.
 - 15 3. The use according to claim 2 wherein the reversible mixed inhibitor of monoamine oxidase A and B is chosen among [3(S),3a(S)]-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1H-oxazolo[3,4-a]quinolin-1-one, (R)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)benzofuran-3-yl]oxazolidin-2-one and (R)-5-methoxymethyl-3-(6-cyclopropylmethoxybenzofuran-3-yl)oxazolidin-2-one.
 - 20 4. Use of a reversible selective inhibitor of monoamine oxidase B according to claim 1.
 5. The use according to claim 4 wherein the reversible selective monoamine oxidase B is chosen among lazabemide, milacemide, caroxazone and IFO.
 - 25 6. The use according to claim 4 wherein the reversible selective monoamine oxidase B is (S)-5-methoxymethyl-3-[6-(4,4,4-trifluorobutoxy)-1,2-benzisoxazol-3-yl]oxazolidin-2-one.
 - 30 7. Use of a reversible selective inhibitor of monoamine oxidase A according to claim 1.
 8. The use according to claim 7 wherein the reversible selective inhibitor of monoamine oxidase A is chosen among befloxatone, moclobemide, brofaromine, phenoxathine, esuprone, befol, RS 8359 (Sankyo), T794 (Tanabe), KP 9 (Krenitsky,

20051220 62769007

USA), E 2011 (Eisei), toloxatone, pirlindole, amiflamine, sercloremine and bazinaprine.

5 9. The use according to claim 7 wherein the reversible selective inhibitor of monoamine oxidase A is befloxatone.

10 10. The use according to claim 9 wherein the dosage amount of befloxatone is from about 2.5 to 40 mg per day.

10 11. The use according to claim 10 wherein the amount of befloxatone to be administered is from 10 to 20 mg.

15 12. The use according to any of claims 1 to 11 wherein the inhibitor of monoamine oxidase is intended for administration by the oral, injectable, transdermal or rectal route.

2005T20" 62T6900F

add A2
add A4